BiondVax Pharmaceuticals Ltd.
BVXV · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $17,643 | $25,115 | $20,181 | $48,577 |
| - Cash | $7,506 | $10,799 | $14,075 | $29,444 |
| + Debt | $24,613 | $23,279 | $21,542 | $62,020 |
| Enterprise Value | $34,750 | $37,595 | $27,648 | $81,153 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $2,016 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,595 | -$3,048 | -$9,274 | $15,957 |
| % Margin | – | – | – | – |
| Net Income | -$3,762 | -$3,844 | $5,597 | $9,792 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.11 | -1.19 | -1.76 | 5.24 |
| % Growth | 6.7% | 32.4% | -133.6% | – |
| Operating Cash Flow | -$2,876 | -$3,059 | $15,851 | – |
| Capital Expenditures | -$377 | -$6 | -$490 | – |
| Free Cash Flow | -$3,253 | -$3,065 | $15,361 | – |